In order to investigate the validity of angiotensin converting enzyme inhibition with captopril as a screening test for primary aldosteronism (PA), 50mg of captopril were administered orally to 7 patients with PA, 17 with essential hypertension (EH), 5 with renovascular hypertension (RVH), 2 with renoparenchymal hypertension (RH) and 8 normal volunteers.
RIMARY aldosteronism (PA), described initially by Conn,1) is a syndrome caused by excessive production of aldosterone from an adrenal tumor. Hypertension, hypokalemic alkalosis, normal output of urinary 17-hydroxycortico-steroids and excessive production of aldosterone were original features of the syndrome. Later, the marked suppression of plasma renin activity (PRA), resulting from plasma volume expansion caused by mineralocorticoid excess, provided a potential tool to detect the surgically curable hypertension of PA.2) However, extensive studies of PRA in hypertensive patients revealed that a considerable population of essential hypertensive (EH) patients showed suppressed PRA in the absence of excess levels of aldosterone. Furthermore, several cases of PA associated with high PRA have been reported,3),4) mostly resulting from renal damage due to longstanding severe hypertension. Thus, the estimation of basal and or stimulated PRA is not adequate to establish the diagnosis of PA. Rather, it is necessary to demonstrate that the production of aldosterone is autonomous to establish the diagnosis of PA. For this purpose, maneuvers to suppress the renin-angiotensin-aldosterone system, such as high salt intake,5) exogenous mineralocorticoid administration6) and acute saline infusion7) have been developed. Among these, the saline infusion test has been nominated as the most simple and reliable method. However, it is sometimes difficult to perform in the severely hypertensive patient. Lyon et al8) have reported that the oral administration of captopril, a potent inhibitor of angiotensin I converting enzyme, might be an alternative method. Both captopril and saline infusion can lower circulating angiotensin II levels and decrease production of aldosterone in EH, renovascular (RVH) and renoparenchymal hypertension (RH). However, these have no effect on aldosterone production in patients with PA because of its independency from the renin angiotensin system.9) We have previously reported10) on the clinical usefulness of the captopril administration test in the diagnosis of PA. Those results were not conclusive because of an insufficient number of patients. The present study was undertaken to confirm the validity of this test to differentiate PA from other forms of hypertension.
PATIENTS AND METHODS
Seven patients with PA, 17 with EH, 5 with RVH, 2 with RH and 8 normal subjects were studied. All patients were admitted to our hospital and underwent detailed physical examination, routine blood tests, urinalysis and several hormonal profilings including PRA, plasma aldosterone concentration (PAC), urinary output of catecholamines, 17 KS and 17 OHCS. Table I . Clinical Data of Individual Subjects 15ng/dl in all patients with EH, RVH, RH and normal controls and greater than 15ng/dl in 6 of 7 patients with PA. The PRA after captopril increased to greater than 1ng/ml/h in normal subjects and all of the RH and RVH Fig.1 . The PAC to PRA ratios before and after 50mg captopril administration in patients with PA, EH, RVH, RH and in normal subjects. patients, whereas it was less than that in 7 of 17 EH patients and 6 of 7 patients with PA. The aldosterone to renin ratios before and after captopril are shown in Table II and Fig.1 . The ratios before captopril were greater than 20 in all the PA and 3 of 17 EH patients and one each of the RH and normal subjects. However, the ratios after captopril were never less than 20 in only the PA patients. This finding was unique to this group.
DISCUSSION
The present study has assessed the usefulness of the captopril administration test in the screening of PA and confirmed its diagnostic accuracy for the disease. When we take into account the ratio of PAC to PRA at 90 min after captopril administration, it seems to be superior to any of the other methods currently used for the purpose. cepted that a more dependable marker to detect PA11) is the suppression of PRA after i.v. furosemide followed by 1 or 2 hours of upright posture, but we failed to distinguish the disease completely from so-called low renin EH. Moreover, some of our female patients were unable to maintain upright posture for 2 hours after furosemide administration. Therefore, a more adequate diagnostic test for PA is needed. Recently, Lyon et al8) have reported on the usefulness of captopril as an alternative tool to diagnose PA. It has been noticed that the drug has no effect on aldosterone production in patients with PA because of the autonomous production of the steroid. We previously reported that the captoprill test was a simple and safe test to evaluate the role of the renin angiotensin system in hypertensive patients.10) Therefore, we concentrated on the usefulness of the drug for the diagnosis of PA. As stated by Lyon et al, 6 of our 7 patients with PA also showed a PAC of greater than 15ng/dl at 90 min after the administration of captopril, while patients with other forms of hypertension did not. However, we still could not diagnose as PA one patient with PA, proven to have an aldosteronoma by operation, using only this criterion. On the other hand, captopril increases PRA by decreasing the negative feedback of angiotensin II in patients with EH, but has little effect on PRA in patients with PA. However, in the present study, 7 of 17 patients with EH failed to increase their PRA above 1ng/ml/h after the administration of captopril, and thus might be classified in the low renin group of EH. Therefore, the response of PRA itself to the drug cannot be a reasonable criterion. Lyon et al8) also proposed the use of an aldosterone to renin ratio of 50 to separate PA from other forms of hypertension. When we used a ratio of 50, 2 of our PA patients had to be grouped in EH. Therefore, it seems a reasonable criterion to use a ratio of 20 in our study because all our patients with PA showed ratios greater than that and none of the patients with other forms of hypertension including EH, RVH and RH had ratios below 20. Further expanded studies will be needed to decide on the proper ratio to be set as the borderline to separate PA patients from others .
It is widely accepted that the lack of suppression of PAC by a saline infusion might be a most reliable diagnostic criterion for PA . However, the test is at times not easily performed in patients with severe hypertension because of the acute loading of 2 liters of saline. In contrast , the captopril test has no marked side effects and can be performed within 2 hours . Therefore, the captopril test might be a convenient, less harmful and more accurate test for the diagnosis of PA. In addition, the effect of sodium intake on the PAC to PRA ratio after captopril is under investigation in an attempt to apply the test to outpatients without the necessity of employing dietary sodium Jpn. Heart J. J uly 1985
manipulation.
